Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma

NCT03473756 | Completed Phase 1 Results DMC FDA Drug

• 2 other identifiers: 191312017-001483-38
• Study Type: interventional
• Target: 37
• Locations: 8 countries
• Sites: 30

Brief Summary

FORT-2 is designed to evaluate safety, efficacy, RP2D and PK of rogaratinib in combination with atezolizumab in patients with untreated FGFR-positive urothelial carcinoma. The study originally comprised two separate parts: Phase 1b (Part A) and Phase 2 (Part B). The study parts differ in design, objectives, and treatment. The primary objectives of this Phase 1b study (Part A) are to determine the safety, tolerability, RP2D and pharmacokinetics of rogaratinib in combination with atezolizumab in these patients. The primary objective of the Part B is to compare progression-free survival (PFS) according to RECIST v1.1 of rogaratinib in combination with atezolizumab over placebo in combination with atezolizumab in untreated patients with FGFR-positive locally advanced or metastatic urothelial carcinoma. Of note, patients who participate in Part A are not allowed to participate in Part B. Part B will be initiated once the data from Part A supports continuation of the study, even if this occurs prior to primary completion of Part A. The sponsor may decide not to continue the study as a whole after completion of Part A if the data do not support further development. Part B of the study will no longer be conducted.

Conditions

Urothelial Carcinoma

Keywords

Locally advanced or metastatic urothelial carcinoma; Bladder cancer; Checkpoint inhibition; FGFR inhibition

Outcome Measures

Primary Outcomes (4)

• Number of Participants With Dose-limiting Toxicities(DLTs)

  Up to 21 days

• Number of Participants With Treatment-emergent Adverse Events (TEAEs)

  up to 90 days after the last study medication intake, an average of 60 days

• Number of Participants With Drug-related TEAEs

  up to 90 days after the last study medication intake, an average of 60 days

• Number of Participants With Treatment-emergent Serious Adverse Events(TESAEs)

  up to 90 days after the last study medication intake, an average of 60 days

Secondary Outcomes (3)

• Objective Response Rate(ORR)

  Up to 5 months

• Maximal Plasma Concentration (Cmax) of Rogaratinib

  At cycle 1 Day 1

• Area Under the Rogaratinib Concentration Versus Time Curve (AUC)

  At cycle 1 Day 1, 0-t(last)

Study Arms (1)

Rogaratinib + Atezolizumab in Part A

EXPERIMENTAL

Part A: Part A is conducted in patients who are cisplatin-ineligible and have had no prior systemic treatment for locally advanced or metastatic disease. Patients will receive rogaratinib plus atezolizumab combination treatment.

Drug: Rogaratinib (BAY1163877); Drug: Atezolizumab

Interventions

Rogaratinib (BAY1163877) DRUG

Part A:Rogaratinib will be administered orally until disease progression, unacceptable toxicity or consent withdrawal. The starting dose of 800 mg b.i.d. will be confirmed using a dose selection design.

Rogaratinib + Atezolizumab in Part A

Atezolizumab DRUG

Part A: A fixed dose of 1200 mg atezolizumab will be administered through intravenous (i.v.) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity or consent withdrawal.

Rogaratinib + Atezolizumab in Part A

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Existence of archival or fresh tumor biopsy specimen for FGFR1/3 mRNA expression testing
• High FGFR1 or 3 mRNA expression levels (RNAscope score of 3+ or 4+) in archival or fresh tumor biopsy specimen
• Documented locally advanced (T4, any N; or any T, N2-3) or metastatic urothelial carcinoma (transitional cell carcinoma) including urinary bladder, renal pelvis, ureters, urethra, meeting all of the following criteria:
• No prior systemic treatment for locally advanced or metastatic urothelial carcinoma. For patients who received prior adjuvant/neoadjuvant chemotherapy or chemo-radiation for urothelial carcinoma, a treatment-free interval \> 12 months between the last treatment administration and the date of recurrence is required in order to be considered treatment-naïve in the metastatic setting. Prior local intra-vesical chemotherapy or prior local immunotherapy is allowed if completed at least 4 weeks before the first study drug administration. Regionally available standard of care options must be considered for all patients.
• Ineligibility for cisplatin-based chemotherapy as defined by any one of the following criteria:
• Impaired renal function (GFR \> 30 but \< 60 mL/min/1.73 m2) according to the modification of diet in renal disease (MDRD) abbreviated formula
• A Hearing loss (measured by audiometry) of \> 25 dB at two contiguous test frequencies in at least one ear.
• Grade ≥ 2 peripheral neuropathy (i.e. sensory alteration or paresthesia including tingling)
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1.

You may not qualify if:

• Active symptomatic or untreated brain metastases as determined by CT or MRI evaluation during screening and prior radiographic assessment.
• History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid syndrome, granulomatosis with polyangiitis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
• History or current condition of an uncontrolled cardiovascular disease including any of the following conditions:
• Congestive heart failure (CHF) NYHA Class 2 or greater, unstable angina (symptoms of angina at rest) or
• New-onset angina (within last 3 months before the first study drug administration)
• Myocardial infarction (MI) within past 6 months before the first study drug administration
• Unstable cardiac arrhythmias requiring anti-arrhythmic therapy.
• Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or known left ventricular ejection fraction \< 50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate.
• Current diagnosis of any retinal disorders including retinal detachment, retinal pigment epithelial detachment (RPED), serous retinopathy or retinal vein occlusion.
• Current evidence of endocrine alteration of calcium phosphate homeostasis (e.g. parathyroid disorder, history of parathyroidectomy, tumor lysis, tumoral calcinosis, paraneoplastic hypercalcemia).
• Concomitant therapies that are known to increase serum calcium or phosphate levels (i.e. antacids, phosphate-containing laxatives oral/rectal, potassium phosphate) and that cannot be discontinued or switched to a different medication before the first study drug administration
• Treatment with systemic corticosteroids or other systemic immunosuppressant medications within 2 weeks before the first study drug administration, or anticipated requirement for systemic immunosuppressive medications during the trial.

Sponsors & Collaborators

• Bayer: lead

Study Sites (30)

University of Arizona Cancer Center

Tucson, Arizona, 85724, United States

Location

UChicago Medicine Comprehensive Cancer Center - Hyde Park

Chicago, Illinois, 60637, United States

Location

Barbara Ann Karmanos Cancer Institute - Detroit Headquarters

Detroit, Michigan, 48201, United States

Location

Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States

Location

Ordensklinikum Linz GmbH Elisabethinen

Linz, Upper Austria, 4020, Austria

Location

Krankenhaus der Barmherzigen Brüder

Vienna, Vienna, 1020, Austria

Location

Uniklinikum Salzburg - Landeskrankenhaus

Salzburg, 5020, Austria

Location

Universitätsklinikum AKH Wien

Vienna, 1090, Austria

Location

Institut Bergonie - Unicancer Nouvelle Aquitaine

Bordeaux, 33076, France

Location

Centre Oscar Lambret - Lille

Lille, 59020, France

Location

Institut de Cancérologie de l'Ouest - Saint Herblain

Saint-Herblain, 44800, France

Location

Universitätsklinikum Köln

Cologne, North Rhine-Westphalia, 50937, Germany

Location

Universitätsklinikum Essen

Essen, North Rhine-Westphalia, 45147, Germany

Location

Universitätsmedizin der Johannes Gutenberg Universität Mainz

Mainz, Rhineland-Palatinate, 55101, Germany

Location

Azienda Ospedaliero Universitaria di Modena

Modena, Emilia-Romagna, 41100, Italy

Location

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, Lombardy, 20133, Italy

Location

Istituto Europeo di Oncologia s.r.l - Sviluppo di nuovi farmaci per Terapie Innovative

Milan, Lombardy, 20141, Italy

Location

Istituto Oncologico Veneto

Padua, Veneto, 35128, Italy

Location

A.O.U.I. Verona

Verona, Veneto, 37134, Italy

Location

National Cancer Center Hospital East

Kashiwa, Chiba, 277-8577, Japan

Location

National Hospital Organization Shikoku Cancer Center

Matsuyama, Ehime, 791-0280, Japan

Location

University of Tsukuba Hospital

Tsukuba, Ibaraki, 305-8576, Japan

Location

The Cancer Institute Hospital of JFCR

Koto-ku, Tokyo, 135-8550, Japan

Location

Severance Hospital, Yonsei University Health System

Seoul, Seoul Teugbyeolsi, 03722, South Korea

Location

Asan Medical Center

Seoul, Seoul Teugbyeolsi, 05505, South Korea

Location

Samsung Medical Center

Seoul, 06351, South Korea

Location

Ciutat Sanitaria i Universitaria de la Vall d'Hebron

Barcelona, 08035, Spain

Location

Hospital Clínic i Provincial de Barcelona

Barcelona, 8036, Spain

Location

Hospital Ramón y Cajal | Oncología

Madrid, 28034, Spain

Location

Hospital General Universitario de Valencia

Valencia, 46014, Spain

Location

Related Publications (2)

• Sweis RF, Gajate P, Morales-Barrera R, Lee JL, Necchi A, de Braud F, Penel N, Grunwald V, Maruzzo M, Meran J, Ishida TC, Bao W, Zhou Y, Ellinghaus P, Rosenberg JE. Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial. JAMA Oncol. 2024 Nov;10(11):1565-1570. doi: 10.1001/jamaoncol.2024.3900. Epub 2024 Sep 19.

  PMID: 39298147 DERIVED

• Grunewald S, Politz O, Bender S, Heroult M, Lustig K, Thuss U, Kneip C, Kopitz C, Zopf D, Collin MP, Boemer U, Ince S, Ellinghaus P, Mumberg D, Hess-Stumpp H, Ziegelbauer K. Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models. Int J Cancer. 2019 Sep 1;145(5):1346-1357. doi: 10.1002/ijc.32224. Epub 2019 Mar 13.

  PMID: 30807645 DERIVED

MeSH Terms

Conditions

Carcinoma, Transitional Cell; Urinary Bladder Neoplasms

Interventions

Rogaratinib; atezolizumab

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urinary Bladder Diseases; Urologic Diseases; Male Urogenital Diseases

Results Point of Contact

• Title: Bayer Clinical Trials Contact
• Organization: Bayer AG

clinical-trials-contact@bayer.com

(+) 1-888-8422937

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Masking Details: Part A is open-label.
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 16, 2018
• First Posted: March 22, 2018
• Study Start: May 15, 2018
• Primary Completion: July 16, 2021
• Study Completion: July 10, 2024
• Last Updated: April 9, 2025
• Results First Posted: April 9, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

DE (3); FR (3); KR (3); AU (4); ES (4); JP (4); US (4); IT (5)